4-chloro-2,3-dinitrobenzoic acid | 102014-48-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-2,3-dinitrobenzoic acid
• CAS: 102014-48-2
• 化学式: C₇H₃ClN₂O₆
• 分子量: 246.564
• InChiKey: HBBWQNAQGBHSHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  129
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-chloro-2,3-dinitrobenzoic acid 在 platinum on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 0.75h， 生成 4-chloro-6,7,8,9-tetrahydrophenazine-1-carboxylic acid
  参考文献：
  名称：

  Bis(phenazine-1-carboxamides):  Structure−Activity Relationships for a New Class of Dual Topoisomerase I/II-Directed Anticancer Drugs

  摘要：

  Ring-substituted bis(phenazine-1-carboxamides), linked by a -(CH2)(3)NMe(CH2)(3)- chain, were prepared from the corresponding substituted phenazine-1-carboxylic acids by reaction of the intermediate imidazolides with bis(3-aminopropyl)methylamine. The compounds were evaluated for growth inhibitory activity in a panel of tumor cell lines, including P388 leukemia, Lewis lung carcinoma, and wild-type (JL(C)) and mutant (JL(A) and JL(D)) forms of human Jurkat leukemia; The latter mutant lines are resistant to topoisomerase (topo) II targeted agents because of lower levels of the enzyme. Analogues with small, lipophilic substituents (e.g,, Me, Cl) at the 9-position were the most potent inhibitors, superior to the corresponding dimeric bis(acridine-4-carboxamides) (bis-DACA analogues). Several of the compounds were preferentially (up to 2-fold) more cytotoxic toward the mutant Jurkat lines than the wild-type. To test whether this selectivity was related to topoisomerase action, the most potent of the compounds (9-methyl) was evaluated in a cell-free system. It poisoned topo I at drug concentrations of 0.25 and 0.5 mu M and inhibited the catalytic activity of both topo I and topo II at concentrations of 1 and 5 mu M, respectively. Results from the NCI human tumor cell line panel showed the compounds had preferential activity toward colon tumor lines ton average 9.5-fold more active in the HT29 line than in the cell line, panel as a whole). Several analogues produced significant growth delays in the relatively refractory subcutaneous colon 38 tumor model in vivo. In particular, the 9-methyl compound was substantially more potent in this tumor model than the clinical dual topo I/II poison DACA (total dose 90 versus 400 mg/kg) with comparable activity. The bis(phenazine-1-carboxamides) are a new and interesting class of dual topo I/II-directed anticancer drugs.

  DOI：

  10.1021/jm990423f
• 作为产物：
  描述：

  4-氯-2-硝基苯甲酸 在 硫酸 、 硝酸 作用下， 反应 1.5h， 生成 4-chloro-2,3-dinitrobenzoic acid
  参考文献：
  名称：

  [EN] POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS
  [FR] ANTAGONISTES DE TLR7/8 POLYCYLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES IMMUNES

  摘要：

  本发明涉及式(I)的化合物及其药学上可接受的组合物，作为Toll样受体7/8（TLR7/8）拮抗剂。在式(I)中，环A是芳基或杂芳基；环B是芳基或杂芳基；X是C(R4)2、O、NR4、S、S(R4)或S(R4)2。

  公开号：

  WO2017106607A1

文献信息

• Alcools aliphatiques optiquement actifs nouveaux et leur utilisation à titre d'ingrédients parfumants
  申请人：FIRMENICH SA

  公开号：EP0457022A1

  公开（公告）日：1991-11-21

  On décrit des composés de formule a) dans laquelle le symbole R³ représente un atome d'hydrogène et le symbole R¹ représente un atome d'hydrogène ou un radical méthyle, sous forme d'un mélange optiquement actif d'épimères en C(3) de formule dans laquelle la ligne ondulée indique l'une ou l'autre des deux orientations possibles du groupe OH, ou sous forme de l'un des épimères en C(3) composant ledit mélange ; ou b) dans laquelle le symbole R³ représente un radical méthyle et le symbole R¹ un atome d'hydrogène, sous forme d'un mélange optiquement actif d'épimères en C(3) de formule dans laquelle la ligne ondulée a le sens indiqué ci-dessus, ou sous forme de l'un des épimères en C(3) composant ledit mélange. Ces composés sont utiles à titre d'ingrédients parfumants et confèrent aux compositions dans lesquelles ils sont incorporés des notes boisées-ambrées. On décrit également des procédés de préparation des espèces optiquement actives susmentionnées.

  式中的化合物 a) 式中符号 R³ 代表氢原子，符号 R¹ 代表氢原子或甲基，以式 C(3) 表聚物的光学活性混合物的形式存在，其中波浪线表示 OH 基团的两种可能取向中的一种或另一种，或以构成上述混合物的其中一种 C(3) 表聚物的形式存在；或 其中波浪线表示 OH 基团两种可能取向中的一种或另一种，或以组成上述混合物的一种 C(3) 表聚物的形式；或 b) 符号 R³ 代表甲基，符号 R¹ 代表氢原子，其形式为式 C(3) 表聚物的光学活性混合物。 其中波浪线具有上述含义，或以组成上述混合物的一种 C(3) 表聚物的形式存在。 这些化合物可用作香料成分，并为含有它们的组合物带来木质琥珀香味。 此外，还介绍了制备上述光学活性物质的工艺。
• Arylating medicaments
  申请人：Radopath Pharmaceuticals International Limited

  公开号：EP1016405A2

  公开（公告）日：2000-07-05

  Various arylating agents having activity in the treatment of cancer and viral infection are disclosed. The active compounds include an aromatic ring having at least one labile leaving group and at least one electrophilic group. Preferred active compounds include chlorobenzenesulphonic acids and optionally halogenated nitrobenzenc compounds. In an anti-viral context, the active compounds have efficacy against HIV infections.

  本研究公开了在治疗癌症和病毒感染方面具有活性的各种芳基化剂。这些活性化合物包括一个芳香环，芳香环上至少有一个易变离去基团和至少一个亲电基团。优选的活性化合物包括氯苯磺酸和可选的卤代硝基苯化合物。在抗病毒方面，活性化合物具有抗艾滋病毒感染的功效。
• TLR7/8 antagonists and uses thereof
  申请人：Merck Patent GmbH

  公开号：US10399957B2

  公开（公告）日：2019-09-03

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.

  本发明涉及可用作 TLR7/8 拮抗剂的式 I 化合物及其药学上可接受的组合物。
• Progress and records in the study of endogenetic mineralization during collisional orogenesis
  作者：Yanjing Chen、Huayong Chen、Yulin Liu、Guangjun Guo、Yong Lai、Shan Qin、Baoling Huang、Zengjie Zheng、Yinghui Sui、Chao Li、Zhen Li、Ping Li、Xin Li、Haihua Wang、Meixiang Zhu、Xiuli Gao、Qiying Wei

  DOI：10.1007/bf02884893

  日期：2000.3

  To develop and perfect the theory of plate tectonics and regional metallogeny, metallogenesis during collisional orogenesis should be thoroughly studied and wilt attract increasing attention of more and more scientists. This paper presents the main aspects of research and discussions on metallogenesis during collisional orogenesis after the development of plate tectonics, and accordingly divides the study history into two stages, i.e. the junior stage during 1971-1990 and the senior stage after 1990. Beginning with the negation of mineralization in the collision regime by Guild (1971), the focus of study was put on whether there occurred any mineralization during collisional orogenesis at the junior stage. At the senior stage, which is initiated by the advance of metallogenic and petrogenic model for collisional orogenesis, scientists begin to pay their attention to the geodynamic mechanism of metallogenesis, spatial and temporal distribution of ore deposits, ore-forming fluidization, relationship between petrogenesis and mineralization in collisional orogenesis, etc, Abundance of typical collisional orogens such as Himalayan, China has best natural conditions to study collisional metallogenesis. Great progress in the study of metallogenesis during collisional orogenesis has been made by Chinese geologists. Therefore, we hope that the Chinese geologists and Chinese governments at various levels to pay more attention to the study of collisional metallogenesis. Some urgent problems are suggested to be solved so as to bring about breakthroughs in the aspects concerned.
• ARYLATING MEDICAMENTS
  申请人：RADOPATH LIMITED

  公开号：EP0700287A1

  公开（公告）日：1996-03-13